Product pipeline includes EVOMELA® (melphalan) for injection, MARQIBO® (vinCRIStine sulfate LIPOSOME injection), ZEVALIN® (ibritumomab tiuxetan) for the greater China market, ENMD-2076 currently in Phase 2 trials, as well as entecavir and the other U.S. ANDA products.
CASI is a U.S. NASDAQ-listed pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world. CASI has offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.
This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.
EVOMELA® (melphalan) for Injection, MARQIBO® (vincristine sulfate LIPOSOME injection), and ZEVALIN® (ibritumomab tiuxetan) are proprietary to Acrotech Biopharma LLC and its affiliates.